Key Drivers
- Strong margins
- Free-cash flow
- Premium valuation
AIAI Summary
Danaher has shifted from a pure “quality compounder” to a catalyst-backed name, with Masimo and reaccelerating bioprocessing giving it real upside, but at ~41x earnings the stock now hinges on flawless integration and sustained growth—if execution slips, multiple compression is the main risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong margins
- •Free-cash flow
- •Premium valuation
Danaher delivers strong margins, cash flow, and moderate leverage, but its premium valuation and intangibles-heavy balance sheet temper upside.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Breakout hold
- •Near-term extended
DHR has turned from a short-term downtrend into a clear uptrend over the last month, breaking above $180, holding gains, and now looking constructive but extended with support at $188-$190 and resistance near $198-$200.
Quick breakout above $180 followed by a sharp run higher into early
Sentiment & News
Key News Insights:
- •Bioprocessing demand
- •Masimo integration
- •Earnings catalyst
Danaher is seeing strong operational momentum, boosted by surging biotech/bioprocessing demand and the accretive $9.9 billion Masimo acquisition, with near-term earnings and integration execution now in focus. #M&A
The news is modestly positive for DHR, as improving order trends and an earnings-accretive acquisition support growth visibility and sentiment
Similar Companies in Healthcare
Other companies in the same sector with AI ratings